biostudies-literatureUnknown110(1)Necchi A<h4>Background</h4>Pazopanib achieved the end point of clinical activity in pretreated patients with urothelial cancer in a single-group, phase 2 trial. The objective was to identify biological predictors of clinical benefit to pazopanib in these patients.<h4>Methods</h4>EDTA blood samples were collected at baseline (T0) and after 4 weeks (T1) of treatment, together with radiological imaging in all 41 patients to analyse plasma circulating angiogenic factor levels by multiplex ELISA plates. Changes from T0 to T1 in marker levels were matched with response with the covariance analysis. Univariable and multivariable analyses evaluated the association with overall survival (OS), adjusted for prespecified clinical variables. Net reclassification improvement (NRI) tested the performance of the British journal of cancer26-33https://www.ebi.ac.uk/biostudies/studies/S-EPMC3887307biostudies-literatureAnalysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.PMC3887307Landoni ESchwartz LHGianni AMLanocita ROrtega CPennati MSacco CZaffaroni NFare EGiannatempo PCrippa FDaidone MGMorosi CSalvioni RMessina CMariani LNicolai NNecchi ASava TRaggi DDe Braud FGfalseAnalysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.<h4>Background</h4>Pazopanib achieved the end point of clinical activity in pretreated patients with urothelial cancer in a single-group, phase 2 trial. The objective was to identify biological predictors of clinical benefit to pazopanib in these patients.<h4>Methods</h4>EDTA blood samples were collected at baseline (T0) and after 4 weeks (T1) of treatment, together with radiological imaging in all 41 patients to analyse plasma circulating angiogenic factor levels by multiplex ELISA plates. Changes from T0 to T1 in marker levels were matched with response with the covariance analysis. Univariable and multivariable analyses evaluated the association with overall survival (OS), adjusted for prespecified clinical variables. Net reclassification improvement (NRI) tested the performance of the 2014-01-01T00:00:00Z2014 Jan2026-05-03T02:10:20.291Z2025-05-29T21:30:49.28ZS-EPMC38873072423194710.1038/bjc.2013.719